The management team appointments come on the heels of multiple recent placements of the Firefly(TM) 3000 system, Cell Bioscience's flagship product for ultrasensitive detection and characterization of proteins in extremely small biological samples. Cell Biosciences began accepting orders for the Firefly 3000 system in late 2007 as part of an early technology access program for leading cell signaling and translational medicine researchers. Participants in the program receive early access to the Firefly 3000 system, which provides unprecedented levels of sensitivity for the analysis of precious samples, such as tissue biopsies, fine-needle tumor aspirates, and stem cells.
To fuel its commercial expansion, the company closed a Series B financing round of $27 million in late 2006, with participation from the Wellcome Trust, Domain Associates, Latterell Venture Partners, Novo Ventures, Posco BioVentures, Mitsui & Co. Venture Partners, RBC Capital Partners and The Vertical Group.
About Cell Biosciences
Cell Biosciences is a private life sciences company focused on nano-proteomics. We are developing instrumentation systems to enable the detection of specific proteins in extremely small biological samples. The company's lead product, the Firefly 3000, is a capillary-based nanofluidic immunoassay platform designed for ultrasensitive detection and characterization of proteins. Cell Biosciences is located in Palo Alto, CA. http://www.cellbiosciences.com
For additional information, please contact Walter Ausserer, Vice President, Marketing, Cell Biosciences, Inc. 650 859-1485.
|SOURCE Cell Biosciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved